Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.05
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.16 -2.7%
Revenue Growth %: -49.8%
Financial Fact:
GROSS PROFIT (LOSS): 422K
Today's EPS Names:
JFIN, KEQU, LASE, More
Revenue Growth %: -49.8%
Financial Fact:
GROSS PROFIT (LOSS): 422K
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.05), versus ($0.07) reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
- Ridgepost Capital acquires Stellus Capital Management for $4B AUM
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
